- Cartherics and Catalent Expand Commercial License Agreement
Apr 9, 2026 · businesswire.com
MELBOURNE, Australia & TAMPA, Fla.--(BUSINESS WIRE)--Cartherics Pty Ltd, a biotechnology company developing off‑the‑shelf immune cell therapies for high‑impact women's diseases, including ovarian cancer and endometriosis, and Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced an enhanced partnership. The companies have signed an amended commercial license agreement enabling the use of a Catalent cGMP‑compliant induced p.
- CARTHERICS AND CATALENT EXPAND COMMERCIAL LICENSE AGREEMENT
Apr 9, 2026
MELBOURNE, AUSTRALIA & TAMPA, FLA.--(BUSINESS WIRE)--CARTHERICS PTY LTD, A BIOTECHNOLOGY COMPANY DEVELOPING OFF‑THE‑SHELF IMMUNE CELL THERAPIES FOR HIGH‑IMPACT WOMEN'S DISEASES, INCLUDING OVARIAN CANCER AND ENDOMETRIOSIS, AND CATALENT, INC., THE LEADER IN ENABLING THE DEVELOPMENT AND SUPPLY OF BETTER TREATMENTS FOR PATIENTS WORLDWIDE, TODAY ANNOUNCED AN ENHANCED PARTNERSHIP. THE COMPANIES HAVE SIGNED AN AMENDED COMMERCIAL LICENSE AGREEMENT ENABLING THE USE OF A CATALENT CGMP‑COMPLIANT INDUCED P.
- Catalent and GelMEDIX Enter Global Partnership for the Development and Clinical Manufacturing of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases
Mar 11, 2026 · businesswire.com
TAMPA, Fla. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catalent and GelMEDIX Enter Global Partnership for manufacturing and development of iPSC-Derived Cell Therapies in Ocular and Retinal Diseases.
- CATALENT AND GELMEDIX ENTER GLOBAL PARTNERSHIP FOR THE DEVELOPMENT AND CLINICAL MANUFACTURING OF IPSC-DERIVED CELL THERAPIES IN OCULAR AND RETINAL DISEASES
Mar 11, 2026
TAMPA, FLA. & CAMBRIDGE, MASS.--(BUSINESS WIRE)--CATALENT AND GELMEDIX ENTER GLOBAL PARTNERSHIP FOR MANUFACTURING AND DEVELOPMENT OF IPSC-DERIVED CELL THERAPIES IN OCULAR AND RETINAL DISEASES.
- SmartCella and Catalent Sign Nonexclusive License Agreement for GMP iPSCs
Jan 12, 2026 · businesswire.com
TULLINGE, Sweden & TAMPA, Fla.--(BUSINESS WIRE)--SmartCella and Catalent have entered a nonexclusive license agreement for induced pluripotent stem cells (iPSCs) for developing regenerative therapies.
- SMARTCELLA AND CATALENT SIGN NONEXCLUSIVE LICENSE AGREEMENT FOR GMP IPSCS
Jan 12, 2026
TULLINGE, SWEDEN & TAMPA, FLA.--(BUSINESS WIRE)--SMARTCELLA AND CATALENT HAVE ENTERED A NONEXCLUSIVE LICENSE AGREEMENT FOR INDUCED PLURIPOTENT STEM CELLS (IPSCS) FOR DEVELOPING REGENERATIVE THERAPIES.
- Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent
Nov 4, 2025 · globenewswire.com
BASKING RIDGE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today highlighted positive preclinical data as announced by Lisata's licensing partner, Catalent, Inc. (“Catalent”), at the 16th Annual World ADC San Diego Conference, held November 3-6, 2025.
- LISATA THERAPEUTICS HIGHLIGHTS POSITIVE PRECLINICAL DATA OF CERTEPETIDE AS PART OF ANTIBODY-DRUG CONJUGATE COMBINATIONS AS REPORTED BY LICENSING PARTNER CATALENT
Nov 4, 2025
BASKING RIDGE, N.J., NOV. 04, 2025 (GLOBE NEWSWIRE) -- LISATA THERAPEUTICS, INC. (NASDAQ: LSTA) (“LISATA” OR THE “COMPANY”), A CLINICAL-STAGE PHARMACEUTICAL COMPANY DEVELOPING INNOVATIVE THERAPIES FOR THE TREATMENT OF ADVANCED SOLID TUMORS AND OTHER SERIOUS DISEASES, TODAY HIGHLIGHTED POSITIVE PRECLINICAL DATA AS ANNOUNCED BY LISATA'S LICENSING PARTNER, CATALENT, INC. (“CATALENT”), AT THE 16TH ANNUAL WORLD ADC SAN DIEGO CONFERENCE, HELD NOVEMBER 3-6, 2025.
- Catalent Debuts New Corporate Brand, Elevating Customer Service Excellence by “Championing the Missions that Matter™”
Oct 28, 2025 · businesswire.com
TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc., a leading global contract development and manufacturing organization, today unveiled its new corporate brand, marking a strategic evolution that underscores the company's commitment to delivering unparalleled customer service and its focus on “championing the missions that matter.” The new approach reflects Catalent's dedication to helping its pharmaceutical, biotech and consumer health customers bring their life-enhancing and life-changing solution.
- CATALENT DEBUTS NEW CORPORATE BRAND, ELEVATING CUSTOMER SERVICE EXCELLENCE BY “CHAMPIONING THE MISSIONS THAT MATTER™”
Oct 28, 2025
TAMPA, FLA.--(BUSINESS WIRE)--CATALENT, INC., A LEADING GLOBAL CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION, TODAY UNVEILED ITS NEW CORPORATE BRAND, MARKING A STRATEGIC EVOLUTION THAT UNDERSCORES THE COMPANY'S COMMITMENT TO DELIVERING UNPARALLELED CUSTOMER SERVICE AND ITS FOCUS ON “CHAMPIONING THE MISSIONS THAT MATTER.” THE NEW APPROACH REFLECTS CATALENT'S DEDICATION TO HELPING ITS PHARMACEUTICAL, BIOTECH AND CONSUMER HEALTH CUSTOMERS BRING THEIR LIFE-ENHANCING AND LIFE-CHANGING SOLUTION.